comprehensive -WSS

comprehensive

author：entertainment 2025-09-30 13:55:22 Page View：12

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： To bolster infectious disease surveillance, genomics powerhouses team up
Next article： Tori Bowie and the unacceptable rates of Black maternal death

leisure time

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

What happened to the House vote on health price transparency?

AlexHogan/STATYou’rereadingthewebeditionofD.C.Diagnosis. Signuphere toreceivethisnewsletterinyourinb

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Fed up with FDA, ALS advocates consider a take

Ademonstrationmarkingthe10thanniversaryoftheformationACTUP,inNewYork.MarkLennihan/APWASHINGTON—NextW

comprehensive

knowledge

leisure time

Fed up with FDA, ALS advocates consider a take